Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
MaxCyte logo in transparent PNG format
Logo de MaxCyte aux formats PNG transparent et SVG vectorisé
Logo de MaxCyte au format PNG transparent
MaxCyte debuts new state-of-the-art headquarters in Maryland's I-270 ...
MaxCyte Adds Two New Non-Executive Directors to Its Board
MaxCyte gets green light for solid tumour cell therapy - PMLiVE
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year ...
MaxCyte Commences Dosing in First Clinical Trial in Solid Tumors - BioSpace
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering ...
Caribou Biosciences and MaxCyte Enter into Clinical and Commercial ...
MaxCyte Signs Strategic Platform License with Lyell | by Lifecare news ...
MaxCyte
MaxCyte (MXCT) Earnings Date and Reports 2026
MXCT Insider Trading | MaxCyte Buys and Sells
Celularity and MaxCyte Sign Strategic Platform License to Advance ...
MaxCyte Debuts New State-of-the-Art Headquarters in Maryland’s | MXCT ...
MaxCyte Announces Strategic Immuno-Oncology Collaboration to Advance ...
MaxCyte | Electroporation system | 자연과학
Newsletter Subscription | MaxCyte
MaxCyte signs SPL deal with TG Therapeutics - Sharecast.com
MaxCyte joins Alliance for mRNA Medicines - Sharecast.com
Resource Library | MaxCyte
MaxCyte (MXCT): Cell Engineering and Biotechnology Solutions
MaxCyte Workflow for Mammalian Display | MaxCyte
MaxCyte Profile | The Scientist
MaxCyte Highlights Innovations in High-throughput Transfection for Cell ...
MaxCyte enters licence agreement with Kamau Therapeutics - Sharecast.com
MaxCyte Signs Strategic Platform License with Curamys
Ignite Your Cell Therapy Development | MaxCyte
MaxCyte Minutes Newsletter - Q3 2022 | This quarter's edition includes ...
MaxCyte Signs Strategic Platform License with Moonlight Bio | MXCT ...
Webinars and Presentations | MaxCyte
Latest News | MaxCyte
MaxCyte Reports First Quarter 2024 Financial Results and
MaxCyte Reports Second Quarter and Half-Year 2023 Financial
MaxCyte Debuts New State-of-the-Art Headquarters in Maryland’s I-270 ...
ISCT Annual Meeting 2025 | MaxCyte
Electroporation Buffers | MaxCyte
MaxCyte, Inc. on LinkedIn: MaxCyte Headquarters Grand Opening
About MaxCyte | MaxCyte
MaxCyte | Best-in-Class Electroporation Systems | MaxCyte, Inc.
MIDAS SHARE TIPS: Medical group MaxCyte has its finger on the pulse ...
MaxCyte | Best-in-Class Electroporation Systems
MaxCyte CEO and Key Executive Team | Craft.co
MaxCyte Workflow for Mammalian Display | MaxCyte | MaxCyte, Inc.
MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to ...
MaxCyte unveils new HQ to expand headcount, manufacturing - Washington ...
MaxCyte Partners With Adicet Bio for Gene-Edited Cell Therapy ...
On the Charge: MaxCyte Celebrates Role in Sickle Cell Therapy Breakthrough
Collaborate With MaxCyte | MaxCyte
MaxCyte for Rapid, High-Yield Cell Line Development
MaxCyte Showcases Innovations in High-Throughput Transfection for Cell ...
Cell Therapy Development | MaxCyte
Protein & Antibody Production | MaxCyte
Our Electroporation Technology | MaxCyte
MaxCyte® Enables Multiplexed NK Cell Engineering | MaxCyte
MaxCyte is proud to welcome PHCbi as our exclusive distributor in Japan ...
Maxcyte Culture | Comparably
Accessories and Kits | MaxCyte
MaxCyte Minutes Newsletter - Q1 2025
MaxCyte (MXCT) - 8 February 2022 - YouTube
MaxCyte, Inc. | MSCRF
上海金檀生物科技有限公司
冷泉港生物科技股份有限公司
上海达迈生物科技有限公司-MaxCyte
MaxCyte, Inc.
MaxCyte: MXCT IPO, Health Care - Provides cell engineering devices and ...
Non-viral Cell Engineering with Stanford University, Touchlight, and ...
MaxCyte: A Pioneer in the Cell Therapy Market
MaxCyte® Scalable Electroporation: A Universal Cell Engineering ...
MaxCyte, Inc. : Quotes, Address, Contact
The 5th International Conference on Base Editing, Prime Editing ...
MaxCyte, Inc. on LinkedIn: Allow us to re-introduce ourselves! For more ...
Featured Holdings – CONSTANCE
Bio-Strategy - delivering technology
Clients — Adjuvant Partners
MaxCyte: Building the Future of Cell and Gene Therapy…
MaxCyte与传奇生物签署战略平台许可协议，加速细胞疗法研发医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
MaxCyte临床级流式电转染系统 - MaxCyte流式电转染 - 北京博为高科生物科技有限公司
NK cell engineering with MaxCyte®
Complex Protein Production with MaxCyte’s ExPERT Platform for ...
Poster: Non-Viral Cell Engineering of Peripheral Blood Natural Killer ...
MaxCyte, NIH NIAID Study Published in Science Translational Medicine ...
Logos of companies starting with the letter M
MaxCyte, Inc. 2023 Q1 - Results - Earnings Call Presentation (NASDAQ ...
Science for Breakfast with MaxCyte: One Platform For High Efficiency ...
MaxCyte, Inc. | LinkedIn
